Cognate BioServices, a contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products, and Cobra Biologics, a CDMO specialized in providing manufacturing services for plasmid DNA and viral vector, have entered into a definitive agreement in which Cognate will acquire all of the outstanding share capital of Cobra.   The transaction creates an industry-leading enhanced services provider delivering drug development and manufacturing solutions ...